MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Global women’s health leader Hologic, Inc. (HOLX) today announced that its Affirm ® Contrast Biopsy Software, which combines contrast-enhanced diagnostic ...
* announces FDA clearance and commercial availability Of Affirm Prone Biopsy System, First 2d/3d Imaging Guided dedicated prone biopsy system Sign up here. * Hologic says has begun installing Affirm ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) will showcase several recent developments in next-generation AI solutions at the 109 th Scientific Assembly and Annual Meeting of the ...
Hologic (HOLX) announced that its Affirm Contrast Biopsy Software, which combines contrast-enhanced diagnostic capabilities with accurate lesion targeting to help streamline workflow and accelerate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback